AstraZeneca
Pharma engages HTA bodies in early-stage drug discussions
October 27, 2010Research and Development, Sales and Marketing Andrew Witty, AstraZeneca, EMA, European Medicines Agency, GlaxoSmithKline, Johnson & Johnson, health technology assessment, hta
Three pharma companies are taking part in a new pilot to harmonise European standards in health technology assessment (HTA). AstraZeneca, …
Cutting-edge cancer treatments showcased at ESMO
October 18, 2010Research and Development AstraZeneca, Boehringer, Cancer, Cancer Conference, Johnson & Johnson, Novartis, personalised medicine
The search for a ‘silver bullet’ against cancer has failed, for now, with the battle against the disease turning instead …
AZ plans heart attack study for Brilique
October 8, 2010Research and Development, Sales and Marketing AstraZeneca, Brilinta, Brilique
AstraZeneca is due to begin enrolling patients into a new study of its oral antiplatelet Brilique (ticagrelor) before the end …
AZ-BMS diabetes drug impresses in phase III trials
October 1, 2010Research and Development, Sales and Marketing AstraZeneca, BMS, dapagliflozin, diabetes
AstraZeneca and Bristol Myers Squibb’s potential first-in-class diabetes drug dapagliflozin has shown strong results in a late stage trial. It …
Late stage cancer drug failure for AstraZeneca
September 27, 2010Sales and Marketing AstraZeneca, prostate cancer, zibotentan
AstraZeneca’s oncology pipeline has suffered a further blow after prostate cancer drug zibotentan failed to meet its primary endpoint of …
Solid results for AstraZeneca’s oral RA drug
September 23, 2010Research and Development AstraZeneca, Rigel, fostamatinib, rheumatoid arthritis
AstraZeneca’s new oral treatment for rheumatoid arthritis has produced solid results in a phase II trial. Fostamatinib is the first …
AZ signs cancer development deal
September 13, 2010Research and Development AstraZeneca, CRT, Cancer Research UK
AstraZeneca has agreed a deal with charity Cancer Research UK to develop a first-in-class cancer treatment. AZD-3965 targets the monocarboxylate …
AZ’s Seroquel extends European licence
September 3, 2010Sales and Marketing AstraZeneca, Seroquel
AstraZeneca’s controversial anti-psychotic drug Seroquel has been given the green light in Europe as an add-on treatment for serious depressive …
AstraZeneca staff to strike over pension cuts
August 17, 2010Sales and Marketing AstraZeneca, pensions
AstraZeneca is reviewing its position after UK trade union members at the company voted to strike over cuts to pension …
AstraZeneca reaches $200m Seroquel settlement
August 10, 2010Sales and Marketing AstraZeneca, Seroquel
AstraZeneca is to pay around £198 million to settle US lawsuits against its troubled anti-psychotic drug Seroquel. The company has …
FDA recommends Brilinta
July 30, 2010Sales and Marketing 2010 financials, AstraZeneca, Brillinta, Q2
FDA advisors have voted in favour of AstraZeneca’s antiplatelet drug Brilinta, which is currently seeking a licence for the reduction …
Dr Bruce Burlington joins AZ board
July 30, 2010Research and Development, Sales and Marketing AstraZeneca, appointment, research and development, sales and marketing
AstraZeneca has appointed former FDA staffer Dr Bruce Burlington to its board as a non-executive director. Dr Burlington spent 17 …
AstraZeneca extends siRNA collaboration
July 14, 2010Research and Development AstraZeneca, RNA, Silence Therapeutics
AstraZeneca has agreed a one-year extension on its siRNA development collaboration with London-based Silence Therapeutics. Silence is a specialist in …
AstraZeneca collaborates on compound library
July 5, 2010Research and Development AstraZeneca, MRC
AstraZeneca and the UK’s Medical Research Council are to share access to their compounds to improve their efforts to find …
European Court upholds AZ Losec judgement
July 2, 2010Sales and Marketing AstraZeneca, Losec, generics
The General Court of the EU has upheld the European Commission’s 2005 decision that AstraZeneca were guilty of blocking cheaper …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
